T
Thomas F. Lüscher
Researcher at University of Zurich
Publications - 1613
Citations - 88517
Thomas F. Lüscher is an academic researcher from University of Zurich. The author has contributed to research in topics: Endothelium & Myocardial infarction. The author has an hindex of 134, co-authored 1560 publications receiving 79034 citations. Previous affiliations of Thomas F. Lüscher include University of Texas Southwestern Medical Center & Durham University.
Papers
More filters
Journal ArticleDOI
Mejora en la estratificación del riesgo tras el implante percutáneo de válvula aórtica mediante una combinación de marcador tumoral CA125 y EuroSCORE logístico
Oliver Husser,Julio Núñez,Christof Burgdorf,Andreas Holzamer,Christian Templin,Thorsten Kessler,Vicente Bodi,Juan Sanchis,Costanza Pellegrini,Andreas Luchner,Lars S. Maier,Christof Schmid,Thomas F. Lüscher,Heribert Schunkert,Adnan Kastrati,Michael Hilker,Christian Hengstenberg +16 more
TL;DR: En this trabajo se evalua el valor pronostico adicional del CA125 sobre the puntuacion EuroSCORE para la prediccion de riesgo a largo plazo.
Journal ArticleDOI
[Blood pressure, renin angiotensin aldosterone system and other cardiovascular risk factors in children of essential hypertensives (author's transl)].
Studer A,Thomas F. Lüscher,Peter Greminger,Frederick H. Epstein,Grimm J,E. P. Leumann,Tenschert W,Walter Siegenthaler,Wilhelm Vetter +8 more
TL;DR: A genetic disposition as being the underlying cause of higher body weight in hypertensives is supported and it is less probable that a higher food intake in hypertensive families is responsible for this phenomenon.
Journal ArticleDOI
Darusentan: a new perspective for treatment of resistant hypertension?
TL;DR: Early clinical results from Phase II studies suggest that darusentan may find a place in the treatment of resistant hypertension.
Journal ArticleDOI
Renal denervation in the management of hypertension in adults. A clinical consensus statement of the ESC Council on Hypertension and the European Association of Percutaneous Cardiovascular Interventions (EAPCI).
Emanuele Barbato,Michel Azizi,Roland E. Schmieder,Lucas Lauder,Michael Böhm,Sofie Brouwers,Rosa Maria Bruno,Dariusz Dudek,Thomas Kahan,David E. Kandzari,Thomas F. Lüscher,Gianfranco Parati,Atul Pathak,Flavio Ribichini,Markus P. Schlaich,Andrew S.P. Sharp,Isabella Sudano,Massimo Volpe,Costas Tsioufis,William Wijns,Felix Mahfoud +20 more
TL;DR: In this article , the authors proposed that renal denervation (RDN) is an adjunct treatment option in uncontrolled resistant hypertension, confirmed by ambulatory BP measurements, despite best efforts at lifestyle and pharmacological interventions.
Journal ArticleDOI
Cardiomyocyte-Specific JunD Overexpression Increases Infarct Size following Ischemia/Reperfusion Cardiac Injury by Downregulating Sirt3.
Alexander Akhmedov,Fabrizio Montecucco,Sarah Costantino,Daria Vdovenko,Ariane Schaub Clerigue,Daniel S. Gaul,Fabienne Burger,Aline Roth,Federico Carbone,Luca Liberale,Mohammad Amrollahi-Sharifabadi,Valerio Gaetano Vellone,Urs Eriksson,Christian M. Matter,Lindsey A. Crowe,Jean-Paul Vallée,Francesco Paneni,Paul M. Vanhoutte,Giovanni G. Camici,François Mach,Thomas F. Lüscher,Thomas F. Lüscher +21 more
TL;DR: Infarct size, systemic and local inflammation, and production of reactive oxygen species, as well as cytosolic and mitochondrial apoptotic pathways were investigated in adult males after myocardial I/R injury, suggesting that JunD is a key regulator of myocardian I-R injury.